Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 3
2008 7
2009 4
2010 7
2011 5
2012 3
2013 6
2014 4
2015 6
2016 5
2017 2
2018 2
2019 2
2020 4
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Monitoring aspirin and clopidogrel response: testing controversies and recommendations.
Karathanos A, Geisler T. Karathanos A, et al. Mol Diagn Ther. 2013 Jun;17(3):123-37. doi: 10.1007/s40291-013-0022-y. Mol Diagn Ther. 2013. PMID: 23588781 Review.
This paper provides a background to the current controversies surrounding the issue of testing for the effectiveness of antiplatelet therapy and reviews the various genetic and phenotype-based laboratory tests to measure aspirin and clopidogrel response and their co …
This paper provides a background to the current controversies surrounding the issue of testing for the effectiveness of antiplatelet therapy …
Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients.
Lewis JP, Backman JD, Reny JL, Bergmeijer TO, Mitchell BD, Ritchie MD, Déry JP, Pakyz RE, Gong L, Ryan K, Kim EY, Aradi D, Fernandez-Cadenas I, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Gawaz M, Bliden KP, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Schwab M, Klein TE, Shuldiner AR; ICPC Investigators. Lewis JP, et al. Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):203-210. doi: 10.1093/ehjcvp/pvz045. Eur Heart J Cardiovasc Pharmacother. 2020. PMID: 31504375 Free PMC article.
Patients who carried eight or more risk alleles were significantly more likely to experience CVEs [odds ratio (OR) = 1.78, 95% confidence interval (CI) 1.14-2.76, P = 0.01] and cardiovascular death (OR = 4.39, 95% CI 1.35-14.27, P = 0.01) compared to patients who carried six or f …
Patients who carried eight or more risk alleles were significantly more likely to experience CVEs [odds ratio (OR) = 1.78, 95% confidence in …
Clopidogrel hyper-response and bleeding risk in neurointerventional procedures.
Goh C, Churilov L, Mitchell P, Dowling R, Yan B. Goh C, et al. AJNR Am J Neuroradiol. 2013 Apr;34(4):721-6. doi: 10.3174/ajnr.A3418. Epub 2012 Dec 28. AJNR Am J Neuroradiol. 2013. PMID: 23275598 Free PMC article. Clinical Trial.
Ten patients (21.3%) developed hemorrhagic complications. Clopidogrel response was higher in patients with a major bleeding complication compared with those with minor or no bleeding (median, 94% versus 24% platelet inhibition; P=.0084). ...
Ten patients (21.3%) developed hemorrhagic complications. Clopidogrel response was higher in patients with a major bleeding co …
P2Y12 antagonism: promises and challenges.
Michelson AD. Michelson AD. Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):s33-8. doi: 10.1161/ATVBAHA.107.160689. Epub 2008 Jan 3. Arterioscler Thromb Vasc Biol. 2008. PMID: 18174449 Review.
However, several challenges remain, including the relatively slow onset of action of clopidogrel and the phenomenon of clopidogrel response variability or "resistance". Novel P2Y12 antagonists, including prasugrel, AZD6140, and cangrelor, have a faster onset of acti …
However, several challenges remain, including the relatively slow onset of action of clopidogrel and the phenomenon of clopidogrel …
Influence of GAS5/MicroRNA-223-3p/P2Y12 Axis on Clopidogrel Response in Coronary Artery Disease.
Liu YL, Hu XL, Song PY, Li H, Li MP, Du YX, Li MY, Ma QL, Peng LM, Song MY, Chen XP. Liu YL, et al. J Am Heart Assoc. 2021 Nov 2;10(21):e021129. doi: 10.1161/JAHA.121.021129. Epub 2021 Oct 29. J Am Heart Assoc. 2021. PMID: 34713722 Free PMC article.
This study aimed to investigate the roles of GAS5 (growth arrest-specific 5) and its rs55829688 polymorphism in clopidogrel response in patients with CAD. Methods and Results A total of 444 patients with CAD receiving dual antiplatelet therapy from 2017 to 2018 were …
This study aimed to investigate the roles of GAS5 (growth arrest-specific 5) and its rs55829688 polymorphism in clopidogrel respon …
Comparison of VerifyNow P2Y12 and thrombelastography for assessing clopidogrel response in stroke patients in China.
Lv HH, Wu S, Liu X, Yang XL, Xu JF, Guan YT, Dong Q, Zheng SL, Jiang JM, Li SX, Luo Z, Li L, An LX, Han Y. Lv HH, et al. Neurol Sci. 2016 Feb;37(2):277-82. doi: 10.1007/s10072-015-2407-7. Epub 2015 Oct 31. Neurol Sci. 2016. PMID: 26520845
The blood samples were taken on the 5-7th day to assess the capability of VerifyNow P2Y12 and TEG for evaluation of clopidogrel response, and all instrument parameters were used to perform correlation analysis. ...
The blood samples were taken on the 5-7th day to assess the capability of VerifyNow P2Y12 and TEG for evaluation of clopidogrel re …
Latest clinical data on testing for high on-treatment platelet reactivity.
Fileti L, Campo G, Valgimigli M. Fileti L, et al. Rev Cardiovasc Med. 2011;12 Suppl 1:S14-22. Rev Cardiovasc Med. 2011. PMID: 22080983 Review.
This may be due in part to a suboptimal response to the drug, with minimal inhibition of platelet aggregation and/or high on-treatment platelet reactivity. Point-of-care testing of clopidogrel response, together with a reliable diagnostic cutoff, can identify patien …
This may be due in part to a suboptimal response to the drug, with minimal inhibition of platelet aggregation and/or high on-treatment plate …
Association between Paraoxonase-1 p.Q192R Polymorphism and Coronary Artery Disease susceptibility in the Colombian Population.
Corredor-Orlandelli D, Sambracos-Parrado S, Mantilla-García S, Tovar-Tirado J, Vega-Ramírez V, Mendoza-Ayús SD, Peña LC, Leal MF, Rodríguez-Carrillo J, León-Torres J, Pardo-Oviedo JM, Parra Abaunza K, Contreras Bravo NC, Ortega-Recalde O, Fonseca Mendoza DJ. Corredor-Orlandelli D, et al. Vasc Health Risk Manag. 2021 Nov 3;17:689-699. doi: 10.2147/VHRM.S330766. eCollection 2021. Vasc Health Risk Manag. 2021. PMID: 34764653 Free PMC article.
The polymorphism p.Q192R has been previously associated with coronary artery disease (CAD) susceptibility and clopidogrel response. PURPOSE: We aimed at investigating the association of PON1 p.Q192R with CAD and clopidogrel response in Colombian popula …
The polymorphism p.Q192R has been previously associated with coronary artery disease (CAD) susceptibility and clopidogrel response …
Different Clopidogrel Response Elicited by Lansoprazole or Esomeprazole in Patients Undergoing Neurointervention with Dual Antiplatelet Therapy.
Nii K, Morinaga Y, Mitsutake T, Inoue R, Higashi T. Nii K, et al. Clin Drug Investig. 2019 Oct;39(10):939-944. doi: 10.1007/s40261-019-00821-5. Clin Drug Investig. 2019. PMID: 31267433
The mean P2Y12 reaction unit was 220.0 64.4 in the lansoprazole group, and 174.5 65.0 in the esomeprazole group; there was a significant difference in the clopidogrel response of patient treated with lansoprazole or esomeprazole (p = 0.005). ...
The mean P2Y12 reaction unit was 220.0 64.4 in the lansoprazole group, and 174.5 65.0 in the esomeprazole group; there was a significant dif …
Most Recent Evidence Behind Aggregometry and Genotyping Methods as Platelet Function Testing for Tailored Anti-Platelet Treatment Among PCI Patients.
Gajda SN, Kołtowski Ł, Tomaniak M. Gajda SN, et al. Adv Clin Exp Med. 2015 Jul-Aug;24(4):687-93. doi: 10.17219/acem/27922. Adv Clin Exp Med. 2015. PMID: 26469115 Free article. Review.
There is proven genetic correlation between some cytochrome enzymes on clopidogrel response. The most widely tested is gene CYP2C19, which produces the enzyme transforming clopidogrel into an active metabolite. ...
There is proven genetic correlation between some cytochrome enzymes on clopidogrel response. The most widely tested is gene CY …
53 results